Article Information
PubMed
History
- Published online June 16, 2008.
Copyright & Usage
© 2008 Canadian Medical Association
Author Information
- Tongtong Wang MSc,
- Jean-Paul Collet PhD MD,
- Stan Shapiro PhD,
- Mark A. Ware MBBS MSc
- From the Departments of Epidemiology and Biostatistics (Wang, Collet, Shapiro), Anesthesia (Ware) and Family Medicine (Ware), McGill University, Montréal, Que.; the Centre for Healthcare Innovation and Improvement (Collet), Children's and Women's Health Centre, University of British Columbia, Vancouver, BC; and the Alan Edwards Centre for Research on Pain (Ware), McGill University, Montréal, Que.
- Correspondence to:
Dr. Mark A. Ware, Alan Edwards Centre for Research on Pain, Rm. E19.145, Montréal General Hospital, 1650 Cedar Ave., Montréal QC H3G 1A4; fax 514 934-8491; mark.ware{at}mail.mcgill.ca
Statistics from Altmetric.com
Cited By...
In this issue
Article tools
Respond to this article
Adverse effects of medical cannabinoids: a systematic review
Jump to section
Related Articles
Cited By...
- Therapeutic use of cannabis, cannabis-derived products and synthetic cannabinoids for rheumatoid arthritis: Protocol for a systematic review
- Cannabinoids for adult cancer-related pain: systematic review and meta-analysis
- Medical cannabis: we need a change in culture and far more government action
- Systematic review of systematic reviews for medical cannabinoids: Pain, nausea and vomiting, spasticity, and harms
- Medical Cannabinoids in Children and Adolescents: A Systematic Review
- Behavioral Characterization of {kappa} Opioid Receptor Agonist Spiradoline and Cannabinoid Receptor Agonist CP55940 Mixtures in Rats
- A Systematic Review of the Respiratory Effects of Inhalational Marijuana
- Combined Treatment with Morphine and {Delta}9-Tetrahydrocannabinol in Rhesus Monkeys: Antinociceptive Tolerance and Withdrawal
- The Impact of Marijuana Policies on Youth: Clinical, Research, and Legal Update
- Cannabis in the Treatment of Rheumatic Diseases: Suggestions for a Reasoned Approach
- Physicians as Gatekeepers in the Use of Medical Marijuana
- Identification of the Synthetic Cannabinoid R(+)WIN55,212-2 as a Novel Regulator of IFN Regulatory Factor 3 Activation and IFN-{beta} Expression: RELEVANCE TO THERAPEUTIC EFFECTS IN MODELS OF MULTIPLE SCLEROSIS
- The adverse effects of cannabinoids: implications for use of medical marijuana